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Abstract
 
Cell adaptation to hypoxia (Hyp) requires activation of transcriptional programs that coordinate
expression of genes involved in oxygen delivery (via angiogenesis) and metabolic adaptation
(via glycolysis). Here, we describe that oxygen availability is a determinant parameter in the
setting of chemotactic responsiveness to stromal-derived factor 1 (CXCL12). Low oxygen con-
centration induces high expression of the CXCL12 receptor, CXC receptor 4 (CXCR4), in
different cell types (monocytes, monocyte-derived macrophages, tumor-associated macro-
phages, endothelial cells, and cancer cells), which is paralleled by increased chemotactic respon-
siveness to its specific ligand. CXCR4 induction by Hyp is dependent on both activation of the
Hyp-inducible factor 1 
 
  
 
and transcript stabilization. In a relay multistep navigation process,
the Hyp–Hyp-inducible factor 1 
 
 
 
–CXCR4 pathway may regulate trafficking in and out of
hypoxic tissue microenvironments.
Key words: cell migration • SDF-1/CXCL12 receptor (CXCR4) • low oxygen concentration • 
hypoxia-inducible factor 1 (HIF-1)
 
Introduction
 
Oxygen homeostasis represents an important organizing
principle for human development and physiology (1). The
essential requirement for oxidative phosphorylation to
generate ATP is balanced by the risk of oxidative damage
to cellular lipids, nucleic acids, and proteins. As a result,
cellular and systemic O
 
2
 
 concentrations are tightly regulated
via short- and long-acting response pathways that affect the
activity and expression of a multitude of cellular proteins
(2). Dysregulation of O
 
2
 
 homeostasis is found in inflammatory
and cardiovascular diseases, cancer, cerebrovascular disease,
and chronic obstructive pulmonary disease. Recent papers
have begun to delineate the molecular basis of cellular and
systemic mechanisms of O
 
2
 
 homeostasis and the most global
regulator identified to date is the transcriptional activator
hypoxia (Hyp)-inducible factor 1 (HIF-1) composed of the
HIF-1
 
 
 
 and HIF-1
 
 
 
 subunits (1, 3).
During migration and invasion of normal and pathological
tissues, cells may encounter different oxygen levels, due to
poor or altered vascularization, and recent evidence has
suggested that chemotaxis is a cell function which may be
affected by oxygen availability (4, 5). Leukocyte trafficking,
an event which plays a central role in fundamental functions
of multicellular organisms, including tissue remodelling,
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defense, and pathology, is orchestrated by a superfamily of
small proteins termed chemokines, which are essential
players in immune and inflammatory reactions as well as in
infections (6–8). Based on a cysteine motif, chemokines
have been classified into a CXC, CC, C, and CX3C fam-
ily, and 
 
 
 
37 members are identified in humans to date.
Chemokines interact with 7 transmembrane domain
G-protein–coupled receptors and, so far, 10 CC (CCR1-
10), 6 CXC (CXCR1-6), 1 CX3C (CXCR1), and 1 C
(XCR1) receptors have been identified (9). Emerging evi-
dence shows that the expression and function of G-pro-
tein–coupled receptors is strictly controlled by cytokines
and other microenvironmental signals, such as Hyp (10–
12), and that the regulation of receptor expression during
cell activation and deactivation is as important as the regu-
lation of chemokine production for tuning the chemokine
system (13).
Experimental and clinical studies point to the funda-
mental pathophysiological role of Hyp in inflammatory
(14, 15) and neoplastic diseases (16). In particular, tumor
Hyp is a consequence of a structurally and functionally dis-
turbed microcirculation and, in some cases, of a reduced
O
 
2
 
-carrying capacity of the blood due to tumor-associated
anemia. Hyp in human tumors by itself has been shown to
contribute to resistance to standard anticancer therapies,
and recent data suggest that O
 
2
 
-deprived tumor cells are
predisposed to a more malignant phenotype (i.e., tumor
cells are likely to be more metastatic and/or invasive; ref-
erence 16). Solid tumors consist of malignant cells and
stroma, which includes new blood vessels, matrix compo-
nents and cells responsible for their production, a fibrin-
gel matrix, and inflammatory leukocytes (17, 18). Thus,
tumor stromal cells encounter low oxygen conditions and,
in particular, tumor-associated macrophages (TAMs) have
been reported to localize preferentially in the hypoxic ar-
eas of tumors (4, 5, 19, 20). Based on this evidence, we in-
vestigated the effect of Hyp on the expression and func-
tion of chemokine receptors. We observed that Hyp
selectively augments CXCR4 expression through HIF-1
activation in human monocytes, macrophages, endothelial
cells, and cancer cells. The identification of the Hyp–HIF-
1
 
 
 
–CXCR4 pathway provides novel insights into the
mechanisms controlling cell migration in hypoxic regions,
with potential relevance in the pathogenesis of human dis-
eases. The Hyp–HIF-1
 
 
 
–CXCR4 pathway is likely to
regulate the migration and localization of diverse cell types
in tissues.
 
Materials and Methods
 
Cells and Culture Conditions.
 
Human monocytes were sepa-
rated from peripheral blood of human healthy donors by Percoll
gradient centrifugation (10). Monocytes (
 
 
 
98% pure as assessed by
morphology) were resuspended at 10
 
7
 
/ml in RPMI 1640 supple-
mented with 10% FBS, 2 mM glutamine, and antibiotics. All
reagents contained 
 
 
 
0.125 EU/ml of endotoxin as checked by
limulus amebocyte lysate assay (Microbiological Associates). Mono-
cyte-derived macrophages (MDMs) were derived from freshly iso-
lated monocytes (3–5 
 
 
 
 10
 
6
 
 cells/ml) after incubation for 5 d in
RPMI 1640 medium supplemented with 10% FBS, 2 mM gluta-
mine, antibiotics, and 40% autologous serum on hydrophobic pet-
riperm plates (Sigma-Aldrich) as described previously (21).
TAMs were obtained from ascitic fluids collected from un-
treated patients with histologically confirmed epithelial ovarian
carcinoma admitted to the Department of Obstetric and Gyne-
cology, S. Gerardo Hospital, Monza, Italy. All patients had cancer
classified as stage II, III, or IV. Ascitic fluid was collected and cen-
trifuged. Cells pellet was resuspended in RPMI 1640 medium
without serum and layered on top of a Ficoll-Hypaque cushion to
prepare mononuclear cells. Purification of peritoneal macro-
phages was further conducted by two subsequent adherence steps
for 45 min each in RPMI 1640 medium without serum. After
adherence procedures, cells were repeatedly washed with saline to
remove all nonadherent cells. The adherent cells were rested with
complete medium overnight at 37
 
 
 
C and subsequently stimulated
as indicated in the test.
Human endothelial cells were obtained from umbilical veins
and cultured as described previously (22). We used routinely con-
fluent cells at second to sixth passages. Cells at the concentration
of 1.5 
 
 
 
 10
 
4
 
/0.2 ml were cultured for 24 h in flat-bottomed 96-
well plates (Falcon) in M199 medium with 20% FCS, supple-
mented with 50 
 
 
 
g/ml of endothelial cell growth supplement
(Collaborative Research Inc.) and 100 
 
 
 
g/ml heparin. Cells were
maintained at 37
 
 
 
C in a humidified incubator containing 20%
O
 
2
 
, 5% CO
 
2
 
, and 75% N
 
2
 
. For hypoxic conditions, cells were
cultured in an atmosphere-controlled culture chamber (Bellco
Glass) containing a gas mixture composed of 94% N
 
2
 
, 5% CO
 
2
 
,
and 1% O
 
2
 
.
Mouse embryonic fibroblasts (MEFs), wild type, and HIF-
1
 
 
 
 
 
/
 
 
 
 were a gift from G. Semenza (The Johns Hopkins Univer-
sity School of Medicine, Baltimore, MD) and were routinely
maintained in DMEM (Invitrogen and Life Technologies) sup-
plemented with 10% heat-inactivated FBS (Whittaker Bioprod-
ucts), 50 IU/ml penicillin, 50 
 
 
 
g/ml streptomycin, and 2 mM
glutamine (all purchased from Invitrogen and Life Technologies).
MCF-7 (human breast cancer cells), CAOV3 (human ovarian
cancer cell line), 786.0 (36), and WT2 human renal cancer cells
(23) were routinely maintained in RPMI 1640 medium (Whit-
taker Bioproducts) supplemented with 5% heat-inactivated FBS,
50 IU/ml penicillin, 50 
 
 
 
g/ml streptomycin, and 2 mM gluta-
mine. Cells were maintained at 37
 
 
 
C in a humidified incubator
containing 20% O
 
2
 
, 5% CO
 
2
 
 in air (referred to as normoxic con-
ditions). Hyp treatment was performed by placing cells in a mod-
ular incubator chamber (Billupus-Rothemberg Inc.) and flushing
with a mixture of 1% O
 
2
 
, 5% CO
 
2
 
, and 94% nitrogen for 20 min.
The chamber was placed at 37
 
 
 
C.
 
FACS
 
®
 
 Analysis. 
 
Cell staining was performed using mouse
monoclonal anti–human CXCR4 antibody (clone 12G5; BD
Biosciences) and an irrelevant isotype-specific control mouse,
IgG2a, 
 
 
 
 (UPC10; Sigma-Aldrich) followed by FITC-conju-
gated, isotype-matched affinity-purified, goat anti–mouse anti-
body (Southern Biotechnology Associates, Inc.).
 
Cytokines and Reagents.
 
Human recombinant CXCL12/stro-
mal-derived factor 1 (SDF-1) and CCL5/regulated on activation
normal T cell expressed and secreted were from PeproTech. Des-
ferrioxamine (DFX) and actinomycin D (used at 1 mg/ml) were
purchased from Sigma-Aldrich.
 
Migration Assay.
 
Monocyte migration was evaluated using a
chemotaxis microchamber technique as described previously (10).
27 ml of chemoattractant solution or control medium (RPMI
1640 with 1% FCS) was added to the lower wells of a chemotaxisT
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chamber (Neuroprobe). A polycarbonate filter (5 
 
 
 
m pore size;
Neuroprobe) was layered onto the wells and covered with a sili-
con gasket and the top plate. 50 ml of cell suspension (1.5 
 
 
 
 10
 
6
 
/
ml fresh human monocytes) was preincubated for 16 h in the
presence of 400 
 
 
 
M DFX and seeded in the upper chamber. The
chamber was incubated at 37
 
 
 
C in air with 5% CO
 
2
 
 for 90 min.
At the end of the incubation, filters were removed and stained
with Diff-Quik (Baxter), and 10 high-power oil immersion fields
were counted. Cancer cell migration was assayed as described
previously (24) by using Falcon transwells (24-well format, 8-
 
 
 
M
pore; BD Biosciences). 0.5 ml of media containing 5 
 
 
 
 10
 
5
 
 cells
was added to the upper chamber, and 0.5 ml of medium alone or
media supplemented with CXCL12 was added to the lower
chamber. After overnight incubation in hypoxic conditions, cells
on the upper surface of the filter were removed using a cotton
wool swab. Migrated cells on the lower surface were stained us-
ing DiffQuick (Dade Behring). For each transwell, the number of
migrated cells in 10 medium-power fields (20
 
 
 
) was counted.
For human umbilical vein endothelial cell (HUVEC) migration
(25), polycarbonate filters (5 
 
 
 
m pore size, polyvinylpyrrolidine
free) were soaked in 0.5 M acetic acid, washed with PBS, incu-
bated for 24 h in 0.01% gelatin (Sigma-Aldrich), and air dried.
CXCL12 and fibrinogen (Sigma-Aldrich) in M199, containing
1% FCS, were seeded in the lower compartment, and 50 
 
 
 
l of
HUVECs (2 
 
 
 
 10
 
6
 
/ml) was added to the upper compartment.
After 6 h of incubation at 37
 
 
 
C, the upper surface of the filter was
scraped with a rubber policeman. The filters were fixed and
stained, and five oil immersion fields (lower surface) were
counted after coding samples.
 
Northern Blot Analysis.
 
Cells were cultured in medium alone
or supplemented with the indicated agents and total RNA was
purified as described previously (10). 10 
 
 
 
g of total RNA from
each sample was electrophoresed under denaturing conditions,
blotted onto Nytran membranes (Schleicher & Schuell), and
cross-linked by UV irradiation. Membranes were prehybridized
at 42
 
 
 
C in hybrisol (Oncor, Inc.) and hybridized overnight with
10
 
6 
 
cpm/ml of 
 
32
 
P-labeled probe. Membranes were washed three
times at room temperature for 10 min in 0.2
 
 
 
 SSC (1
 
 
 
 SSC 
 
 
 
0.15 M NaCl, 0.015 M of sodium citrate, pH 7.0), 0.1% SDS,
and twice at 60
 
 
 
C for 20 min in 0.2
 
 
 
 SSC, 0.1% SDS before be-
ing autoradiographed using films and intensifier screens at 
 
 
 
80
 
 
 
C
(XAR-5; Kodak). cDNAs were labeled by random priming using
a commercial kit (Boehringer) and 
 
 
 
-[
 
32
 
P]dCTP (3,000 Ci/
mmol; Amersham Biosciences). CCR1 and CCR5 cDNAs were
obtained as described previously (11). CXCR4 cDNA was pro-
vided by T.N.C. Wells (Serono Pharmaceutical Research Insti-
tute, Geneva, Switzerland). Densitometric analysis was per-
formed with a scanning densitometer (model GS300; Hoefer
Scientific Instruments).
 
Transient Transfection.
 
DNA plasmids were prepared using a
commercially available kit (Endofree Maxi-Prep; QIAGEN).
Transfections were performed using effectene transfection re-
agents (QIAGEN) according to the manufacturer’s instructions.
Cells were seeded at a concentration of 5 
 
 
 
 10
 
4
 
 per well in 48-
well plates the day before transfection. 24 h after transfection,
reagents were removed, and cells were allowed to recover for
8 h before being treated for 16–24 h. Cotransfection experiments
were performed using a 1:1 ratio between the reporter plasmid
and HIF-1
 
 
 
 expression vector. Luciferase reporter assays were
performed in 96-well optiplates (Packard Instrument Co.) using
a luciferase assay system (Promega) according to the manufac-
turer’s instructions. Results were normalized for the protein
content using the protein assay (Bio-Rad Laboratories). Re-
porter gene assay pGL–Hyp responsive element (HRE) plasmid
contains three copies of the canonical HRE (5
 
 
 
-GTGAC-
TACGTGCTGCCTAG-3
 
 
 
) from the inducible nitric oxide
synthase promoter (26). pCXCR4 plasmid, containing a 2.6-kb
fragment from the human CXCR4 promoter upstream of the
luciferase reporter gene, was obtained from A.J. Caruz (Univer-
sidad de Jaen, Madrid, Spain; reference 27). HIF-1 
 
 
 
 (ODD
 
 
 
)
expression vector was obtained from E. Huang (Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA; ref-
erence 28). The pCMV(HA)–HIF-1
 
 
 
 expression vector was
obtained from D. Livingston (Dana Farber Cancer Institute,
Boston, MA).
 
Chromatin Immunoprecipitation Assay (ChIP).
 
ChIP assays was
performed in CAOV3 cells, transiently transfected with the
p(HA)HIF-1
 
 
 
 expression vector, and performed as described
previously (29). In brief, 4 
 
 
 
 10
 
6
 
 cells were fixed by adding di-
rectly to the medium formaldehyde (formaldehyde from a 37%
formaldehyde/10% methanol stock; Calbiochem) to a final con-
centration of 1%. After 10 min, ice-cold PBS was immediately
added, plates were transferred on ice and washed extensively with
PBS, and cells were collected. After centrifugation, cells were
lysed for 5 min in L1 buffer (50 mM Tris, pH 8.0, 2 mM EDTA,
0.1% NP-40, and 10% Glycerol) supplemented with protease in-
hibitors. Nuclei were pelleted at 3,000 rpm in microfuge and re-
suspended in L2 buffer (50 mM Tris, pH 8.0, 1% SDS, and 5 mM
EDTA). Chromatin was sheared by sonication (5 
 
 
 
 10 s at one
fifth of the maximum potency in a Sonics vibracell VC13
equipped with a 3-mm tip), centrifuged to pellet debris, and di-
luted ten times in dilution buffer (50 mM Tris, pH 8.0, 0.5% NP-
40, 0.2 M NaCl, and 0.5 mM EDTA). Extracts were precleared
for 2 h with 80 
 
 
 
l of a 50% suspension of salmon sperm DNA–
saturated protein A. Immunoprecipitations were performed at
4
 
 
 
C overnight with 2 
 
 
 
g of polyclonal anti–human hemagglutin
antibody (Santa Cruz Biotechnology, Inc.). Immune complexes
were collected with salmon sperm DNA–saturated protein A, and
washed three times (5 min each) with high salt buffer (washing
buffer: 20 mM Tris, pH 8.0, 0.1% SDS, 1% NP-40, 2 mM
EDTA, and 500 mM NaCl), two times with a 0.5 M LiCl buffer,
and three times with low salt buffer (1
 
 
 
 TE). Immune complexes
were extracted in 1
 
 
 
 TE containing 2% SDS and protein; DNA
cross-links were reverted by heating at 65
 
 
 
C for 6 h. After pro-
teinase K digestion (100 
 
 
 
g, 1–2 h at 50
 
 
 
C), DNA was extracted
by phenol, chloroform, and ethanol precipitated. Approximately
1/20 of the immunoprecipitated DNA was used in each PCR.
Sequences of promoter-specific primers included the CXCR4
promoter region 
 
 
 
1860 to 
 
 
 
1578 as follows: CXCR4, sense,
5
 
 
 
-TCGTGCCAAAGCTTGTCCCTG-3
 
 
 
; and CXCR4, anti-
sense, 5
 
 -GCGGTAACCAATTCGCGAATAGTGC-3 .
Real-time PCR. Total RNA from MEFs, 786.0, and WT2
cells was obtained using an RNA mini kit (QIAGEN). RT-PCR
was performed using a RT-PCR kit (PE Biosystems) as described
previously (30). To measure the human vascular endothelial
growth factor (VEGF), human CXCR4 and mouse CXCR4 ex-
pression real-time PCR was performed using a sequence detec-
tor (ABI-Prism, model 7700; Applied Biosystems). The follow-
ing primers were used: human CXCR4, forward, 5 -GCA-
TGACGGACAAGTACAGGCT-3 , reverse, 5 -AAAGTAC-
CAGTTTGCCACGGC-3 ; and mouse CXCR4, forward, 5 -
TTGTCCACGCCACCAACAGTCA-3 , reverse, 5 -TGAAA-
CACCACCATCCACAGGC-3 . Detection of 18S rRNA, used
as internal control, was performed using premixed reagents from
Applied Biosystems. Detection of VEGF and 18S rRNA was per-
formed using a PCR master mix (TaqMan Universal; AppliedT
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Biosystems) and CXCR4 detection was also performed using a
PCR master mix (SyBr Green; Applied Biosystems). Detection of
SDF-1/CCL12 expression by the MCF7 and CAOV3 cell lines
was performed by using a PCR master mix (SyBr Green; Applied
Biosystem), and the following primers were used: human
CXCL12, forward, 5 -ACACTCCAAACTGTGCCCTTCA-
3 ; and human CXCL12, reverse, 5 -CCACGTCTTTGC-
CCTTTCATC-3 .
Laser Confocal Microscopic Analysis of CXCR4 Expression. Cells
growing on sterile coverslips were washed with PBS after 16-h
incubation in Hyp or Norm conditions as indicated in the text.
Non-specific sites were blocked by 10-min incubation at room
temperature with wash buffer containing 0.9% wt/vol sodium
chloride, 1% vol/vol human serum, and 0.02% wt/vol sodium
azide. Thereafter, the cells were stained with mouse anti–human
CXCR4 antibodies (BD Biosciences) at a dilution of 1:20 for 30
min at room temperature. The cells were washed twice with 2 ml
of wash buffer and incubated with goat F(ab )2 anti–mouse Ig-
FITC (human adsorbed) at a dilution of 1:20 for another 30 min
at room temperature. After two changes in wash buffer, the cells
were fixed in 4% wt/vol paraformaldehyde for 15 min, and the
coverslips were mounted on glass slides for microscopy. Images
were visualized using a system with differential interference con-
trast (FV500; Olympus).
Results
Hyp-increased CXCR4 Expression in Mononuclear Phago-
cytes. As shown in Fig. 1 A, human monocytes cultured
in Hyp, for periods of 4 and 6 h, showed a strong increase
in the expression of CXCR4 mRNA, as compared with
normoxia (Norm)-cultured monocytes (20% oxygen).
Hyp-mediated up-regulation of CXCR4 mRNA was still
present at 16 h. In Hyp, a slight increase was also observed
for CCR1 mRNA expression, whereas CCR5 mRNA
Figure 1. Effect of hypoxia (Hyp) on
CXCR4 expression by fresh human mono-
cytes. (A) Fresh human monocytes obtained
from peripheral blood of healthy donors were
cultured for different times in normoxia
(Norm) or hypoxic (Hyp) conditions, as indi-
cated. Total RNA was analyzed by Northern
blot for CXCR4, CCR1, and CCR5 mRNA
expression. (B) Total RNA from fresh human
monocytes cultured for 4 h in the presence of
increasing concentration of DFX was analyzed
by Northern blot. (C) Hyp- and DFX-induced
CXCR4 surface expression in fresh human
monocytes. Cells were cultured for 16 h in the
indicated conditions and analyzed for CXCR4
surface expression. Surface expression was deter-
mined by flow cytometry using a mouse mono-
clonal antibody anti–human CXCR4. The results
are representative of three independent experi-
ments. (dotted line) Irrelevant antibody. (con-
tinuous line) Norm. (shaded region) Hyp or
DFX. (D) Effect of DFX on the chemotactic
response of monocytes to 100 ng/ml CXCL12,
100 ng/ml CCL5, and 10 8 M FMLP. Cells
were cultured for 16 h in the presence of 400
 M DFX. Migration of monocytes was assayed
by chemotaxis microchamber technique. Results
are mean   SD of five experiments. *, P   0.05
versus cells cultured in normoxic conditions
(paired Student’s t test). (E) Effect of reoxygen-
ation on CXCR4 surface expression. Fresh
human monocytes were cultured for 16 h in
Hyp and subsequently reexposed to Norm for
the indicated times. CXCR4 surface expression
was determined by flow cytometry.T
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level was unaffected. Moreover, Hyp down-regulates re-
sponsiveness of monocytes to CCR2 agonists (4, 5).
Therefore, we focused our attention on the CXCR4 re-
ceptor. The iron chelator DFX is recognized as an Hyp-
mimicking compound (30). Incubation of fresh human
monocytes for 4 h in the presence of DFX resulted in a
dose-dependent increase of the CXCR4 mRNA levels
(Fig. 1 B). Together, these results show that CXCR4
mRNA expression is selectively controlled by changes in
oxygen levels. Modulation of CXCR4 by Hyp was con-
firmed at the protein level by flow cytometry. To evaluate
the functional effects of Hyp on CXCR4, monocytes
were incubated in hypoxic conditions and CXCR4 sur-
face expression was determined. As shown in Fig. 1 C,
exposure of monocytes for 16 h to Hyp resulted in a
strong increase of CXCR4 surface expression. Similarly,
cells incubated in the presence of 400  M DFX for the
same duration showed a significant increase of CXCR4
surface expression. In contrast, neither Hyp nor DFX
treatment affected CCR1 and CCR5 surface expression.
The observed DFX-dependent increase of CXCR4 sur-
face expression was paralleled by a rise in the number
of monocytes migrating in response to CXCL12 (Fig. 1
D). The increased chemotactic responsiveness toward
CXCL12 was specific, whereas both CCL5 (regulated on
activation normal T cell expressed and secreted) and
FMLP-induced migration were not significantly affected.
Thus, in human monocytes, low oxygen conditions result
in a specific up-regulation of the CXCR4 expression and
function. As it was important to assess the reversibility of
Hyp on the induction of CXCR4 expression, we deter-
mined the effect of reoxygenation on the levels of
CXCR4 surface expression in fresh human monocytes. As
shown in Fig. 1 E, after culture in hypoxic conditions for
16 h and reoxygenation, monocytes retained high levels of
CXCR4 for 8 h. Higher levels than control were still
present at 16 h, and returned to baseline by 24 h (unpub-
lished data).
Monocytes differentiate into macrophages during infil-
tration of tissues. As tissues are characterized by lower oxy-
gen concentrations in comparison with peripheral circula-
tion (1), it was important to determine whether CXCR4
up-regulation in response to low oxygen conditions could
be applied also to macrophages. CXCR4 expression in
Hyp was determined in fresh human monocytes, in vitro–
differentiated MDMs, and TAMs obtained from the ascitic
fluid of human ovarian carcinoma. Cells were cultured for
4 h in Norm or Hyp, and total RNA was analyzed for
CXCR4 mRNA expression by Northern blot. As shown
in Fig. 2, hypoxic conditions resulted in a strong up-regu-
lation of the CXCR4 mRNA levels in all the three cell
populations (Fig. 2 A). These results were confirmed by la-
ser confocal microscopy Fig. 2 (B and C), wherein Hyp in-
duced a strong up-regulation of CXCR4 surface expres-
sion, in both MDMs and TAMs. Clearly, Hyp controls
CXCR4 expression in mononuclear phagocytes at differ-
ent stages of differentiation.
Hyp-increased CXCR4 Expression in HUVECs.
CXCL12 is a potent chemoattractant for endothelial cells
of different origin and participates in angiogenesis (31, 32).
We investigated the effect of Hyp on CXCR4 expression
by endothelial cells. As shown in Fig. 3, HUVECs, cul-
tured in Hyp or in the presence of 400  M DFX for 4–16 h,
showed increased CXCR4 mRNA expression, as com-
pared with normoxic conditions. VEGF gene expression is
induced by Hyp (1) and served as an internal control. As
expected, VEGF mRNA levels were up-regulated either
by Hyp or DFX. Next, CXCR4 surface expression was
analyzed by laser confocal microscopy. As shown in Fig. 3
B, after Hyp and DFX treatment, CXCR4 surface expres-
sion in endothelial cells was strongly increased. Endothelial
cell recruitment represents an initial step of the process of
angiogenesis. HUVECs cultured in Norm or Hyp were
tested for their capability to migrate in response to
CXCL12. As shown in Fig. 3 C, the number of migrated
Figure 2. Effect of Hyp on CXCR4 expression by fresh human
monocytes (mono), monocyte-derived macrophages (MDMs), and tumor-
associated macrophages (TAMs). (A) Cells were cultured for 4 h in Hyp,
and total RNA was analyzed by Northern blot for CXCR4 mRNA
expression. MDM (B) and TAMs from ascitic fluid of human ovarian
cancer (C) were cultured for 16 h in Norm, Hyp, or in the presence of
400  M DFX, as indicated. CXCR4 surface staining was performed and
detected by laser confocal microscopy. Staining with both isotype-
matched control antibodies was done for all samples (not depicted).T
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Hypoxia Regulation of CXCR4 1396
HUVECs in response to CXCL12 was significantly higher
in hypoxic conditions, at concentrations ranging from 1 to
100 ng/ml. CXCL12 was  100-fold more effective at
eliciting HUVEC migration under Hyp than under nor-
moxic conditions. Migration elicited by fibrinogen, used as
a control, was not affected.
Hyp-increased CXCR4 Expression in Cancer Cells. Che-
mokine receptors may act as molecular tools exploited by
cancer cells to metastasize to target organs (33). In particu-
lar, CXCR4 was shown to play a major role in the migra-
tion of breast cancer cells from the primary tumor to sec-
ondary metastatic sites, such as lung, liver, and bone. As
solid tumors are often characterized by the presence of ne-
crotic areas with low oxygen tension, we reasoned that
Hyp may be a potential mechanism that up-regulates ex-
pression of chemokine receptors in cancer cells localized in
poorly avascularized and oxygenated areas of tumors. To
test this hypothesis, we investigated the level of CXCR4
mRNA expression in response to Hyp in the ovarian can-
cer cell line CAOV3 (Fig. 4). As shown in Fig. 4 A,
CAOV3 cells showed up-regulation of CXCR4 mRNA
after 4 h of culture under hypoxic conditions, which was
paralleled by a significant increase in the surface expression
of this receptor, as demonstrated by cytofluorimetric analy-
sis (Fig. 4 B). The Hyp-induced expression of CXCR4 in
the CAOV3 cells correlated with an increased migration of
these cells toward CXCL12 in the chemotaxis assay (Fig. 4
C). Similar results were obtained with the MCF-7 breast
cancer cell line (unpublished data). Fig. 4 D shows the ef-
fect of Hyp on CXCL12 expression by the same cancer cell
lines MCF7 and CAOV3.
CXCR4 expression by cancer cells may play an impor-
tant role in the metastatic process (33). The process of me-
tastasis formation includes the exit of cancer cells from the
primary tumor site and their entrance into the circulation,
where the oxygen levels will markedly increase, relative to
those present in the tumor microenvironment. To assess
the impact that the exposure of cancer cells to reoxygen-
ation had on the CXCR4 surface expression, CAOV3 cells
were cultured in hypoxic conditions for 16 h and subse-
quently exposed to Norm for up to 14 h. As shown in Fig.
4 E, Hyp-increased CXCR4 surface expression in CAOV3
cells was retained after reoxygenation for 14 h and returned
to baseline by 24 h (not depicted).
Involvement of HIF-1  in Hyp-induced Expression of
CXCR4. HIF-1 is a key regulator of the transcriptional
response to Hyp. To investigate the role of HIF-1 in the
hypoxic induction of CXCR4, MEFs from WT or defi-
cient animals for the   subunit of HIF-1 were incubated
under normoxic or hypoxic conditions for 6 h, and total
RNA was tested for VEGF and CXCR4 mRNA levels by
real-time PCR. As shown in Fig. 5 A, MEFs from WT
animals, but not from HIF-1  KO mice, expressed 3.5-
fold-higher levels of VEGF mRNA when incubated under
hypoxic conditions relative to levels expressed in nor-
moxic conditions. Likewise, MEFs from WT mice ex-
pressed 2.5-fold-higher levels of CXCR4 mRNA when
cultured under hypoxic conditions relative to normoxic
conditions. In contrast, in MEFs from HIF-1  /  mice,
the hypoxic induction of CXCR4 mRNA was no longer
apparent. Furthermore, DFX also induced VEGF and
CXCR4 mRNA in HIF-1 WT cells (6.5- and 7.2-fold,
respectively) but not in HIF-1  /  cells (Fig. 5 B). These
data suggest a role for HIF-1 in the induction of CXCR4
mRNA expression by Hyp.
The von Hippel–Lindau tumor suppressor protein
(VHL) is involved in the degradation of HIF- ; mutations
of VHLs are associated with high levels of HIF-1  protein
and transcriptional activity (34, 35). Therefore, we tested
the expression of CXCR4 mRNA in the renal cancer cell
line 786.0 (VHL mutated; reference 36) and the WT2 cell
line (in which a WT VHL has been reintroduced). These
cells have been extensively used in several laboratories as
Figure 3. Effect of Hyp on CXCR4 expression by human endothelial
venules (HUVECs). (A) Cells were cultured for 4, 8, and 16 h under
Norm, Hyp, or in the presence of 400  M DFX, respectively. Thereafter,
total RNA was analyzed by Northern blot for CXCR4 and VEGF mRNAs
expression. (B) HUVECs were cultured for 16 h in Norm, Hyp, and in
the presence of 400  M DFX, as indicated. CXCR4 surface staining was
performed and detected by laser confocal microscopy. (C) Effect of Hyp
on the chemotactic response of HUVECs to CXCL12. Cells were cultured
for 16 h in hypoxic conditions. Fibrinogen was used as a reference attractant.
Results are mean   SD of three experiments.T
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prototype in which high levels of HIF-1 activity are associ-
ated with increased levels of expression of HIF-1–inducible
genes (23). As reported previously (37), 786.0 cells ex-
pressed high constitutive levels of VEGF mRNA that were
significantly lower ( 60%) in WT2 cells (Fig. 5 C). Ac-
cordingly, 786.0 cells expressed higher levels of CXCR4
mRNA relative to WT2 cells, in which we observed
 65% reduction in three independent experiments. These
data again are consistent with the involvement of HIF-1 in
the hypoxic regulation of CXCR4 mRNA expression. We
investigated the role of HIF-1 in the transcriptional activa-
tion of CXCR4 promoter. MCF-7 breast carcinoma cells,
in which Hyp augments expression of CXCR4 mRNA
(unpublished data), were transiently transfected with a plas-
mids containing a 2.6-kb fragment of the CXCR4 pro-
moter linked to the luciferase reporter gene and incubated
under normoxic or hypoxic conditions for 24 h. As shown
in Fig. 5 D, Hyp induced fourfold higher levels of lu-
ciferase expression relative to cells cultured under nor-
moxic conditions. Interestingly, cotransfection of a HIF-1 
expression vector significantly increased luciferase expres-
sion driven by the 2.6-kb CXCR4 promoter under nor-
moxic conditions (approximately fourfold relative to con-
trol). Hyp further increased luciferase expression induced
by HIF-1  cotransfection up to ninefold compared to un-
treated normoxic cells. Experiments conducted in parallel
using a plasmid containing three copies of a canonical Hyp-
responsive element upstream of the luciferase reporter gene
showed a similar trend of luciferase expression, although
levels of induction were substantially higher.
To obtain direct evidence for the interaction between
HIF-1  and the CXCR4 promoter, we used the ChIP as-
say to measure the HIF-1  recruitment to the CXCR4
promoter. CAOV3 cells, either cultured in Norm or Hyp
for different times, were fixed in formaldehyde, and subse-
quently analyzed by ChIP. Although no interaction be-
tween HIF-1  and the CXCR4 promoter was observed in
Norm, recruitment of HIF-1  to the CXCR4 promoter
was clearly detected at 4 h after Hyp, in the promoter re-
gion  1860 to  1578 (Fig. 5 E). This result is consistent
with the functional data obtained in transient transfection
experiments (Fig. 5 D). Moreover, the HIF-1  inhibitor
Topotecan (38), was able to prevent the Hyp-induced up-
regulation of CXCR4 in CAOV3 cells (unpublished data).
Overall these data demonstrate the involvement of HIF-1 
in the induction of CXCR4 promoter.
Effect of Hyp and DFX on CXCR4 mRNA Stability.
To further investigate the mechanisms of Hyp action, we
estimated its effects on CXCR4 mRNA stability (Fig. 6).
Fresh human monocytes were cultured either in Norm or
Hyp in the presence or absence of 1  g/ml actinomycin D.
Total RNA was extracted at different times as indicated.
The mRNA decay observed in Hyp conditions was com-
pared with the rate of mRNA degradation observed in
Figure 4. Effects of Hyp on CXCR4 expression by
cancer cells. The ovarian cancer cell line CAOV3 was
cultured in normoxic or hypoxic conditions and ana-
lyzed respectively for both CXCR4 mRNA expression
(A) and CXCR4 surface expression (B). (A) cells were
cultured for 4 h in normoxia (Norm) or hypoxic (Hyp)
conditions, as indicated. Total RNA was analyzed by
Northern blot for CXCR4. (B) Cells were cultured for
16 h in Norm or hypoxic (Hyp) conditions. After this
period, CXCR4 surface expression was determined by
flow cytometry. (dotted line) Irrelevant antibody. (con-
tinuous line) Norm. (shaded region) Hyp. (C) Effect of
Hyp on the chemotactic response of CAOV3 ovarian
cancer cells to 100 ng/ml CXCL12. Cells were incubated
overnight in Hyp condition and migration determined
by Transwells, as described in Materials and Methods.
Results are mean   SD of three experiments. *, P   0.05
versus cells cultured in normoxic conditions (Paired
Student’s  t test). (D) Effects of Hyp on CXCL12
mRNA expression by MCF-7 and CAOV3 cells. Cells
were incubated for 4 h in Norm and Hyp as indicated,
and CXCR4 gene expression was next determined by
real-time PCR. Results are representative of two in-
dependent experiments. Values are expressed as fold
increases relative to the reference sample (Norm). (E)
Sustained Hyp-induced CXCR4 expression upon reoxy-
genation. CAOV3 cells were cultured under Norm or
Hyp conditions for 16 h. Thereafter, the cells were
exposed to Norm for a further 14 h and stained for
CXCR4 expression. The figure shows a representative
field using confocal microscopy. CAOV3 cells stained
for CXCR4 (blue fluorescence) and nuclei (red fluo-
rescence). The bottom panels in each group shows
phase-contrast images merged with fluorescence readings.T
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normoxic conditions. The results indicate that Hyp in-
creased CXCR4 mRNA stability, suggesting that Hyp-
induced CXCR4 mRNA expression relies on both tran-
scriptional and posttranscriptional mechanisms.
Discussion
Regulation of cell migration by changes in oxygen avail-
ability is a central event during the organization of host re-
sponse in inflammatory and neoplastic diseases as it may in-
fluence leukocyte recruitment and activation, angiogenesis,
and metastasis formation (16). Here, we report that Hyp
mediates selective up-regulation of CXCR4 in different
cell types, including mononuclear phagocytes (monocytes,
MDMs, and TAMs), endothelial cells, and cancer cells, and
demonstrate that oxygen levels act as an important regula-
tor of CXCR4 receptor expression. Our data also indicate
Figure 5. Role of HIF-1  in the regulation
of CXCR4 gene expression. (A) Expression
of CXCR4 in HIF-1  KO mouse embryo
fibroblast. Mouse embryo fibroblast from
wild type (MEF / ) or knockout for the  
subunit of HIF-1 (MEF / ) were incubated
under normoxic or hypoxic conditions for
6 h, and total RNA was tested for VEGF and
CXCR4 mRNA levels by real-time PCR.
(B) DFX was used as Hyp-inducing agent.
Results are the average of three independent
experiments. (C) Expression of CXCR4 in
VHL WT and mutated renal carcinoma
cells. Expression of CXCR4 and VEGF
mRNAs was tested by real-time PCR in
the renal cancer cell line 786.0 (VHL mu-
tated) and WT2 (in which a WT VHL has
been reintroduced). Results are the average
of three independent experiments. (D) HIF-
1–dependent transcriptional activation of
CXCR4 promoter. MCF-7 breast carcinoma
cells were transiently transfected with a plas-
mid containing a 2.6 kb fragment of the
CXCR4 promoter linked to the luciferase
reporter gene, with or without a HIF-1 
expression vector. Cells were incubated under
normoxic or hypoxic conditions for 24 h
and evaluated for the luciferase activity.
Results are the average of three independent
experiments. (E) Hyp-induced HIF-1 
recruitment to the CXCR4 promoter.
CAOV3 cells transfected with the
p(HA)HIF-1  plasmid were cultured for
4 h in normoxic or hypoxic conditions.
ChIP  was performed to investigate the re-
cruitment of HIF-1  on the CXCR4 pro-
moter. (lane 1) Untransfected. (lane 2) Norm.
(lane 3) Hyp.
Figure 6. Stabilization of CXCR4 mRNA by Hyp. (A) Fresh human
monocytes were cultured for 4 h under Norm or Hyp, and in the pres-
ence or absence of 1  g/ml actinomycin D (ActD). Thereafter, total
RNA was extracted at different times as indicated and analyzed by North-
ern blot for CXCR4 mRNA expression. (B) Densitometric analysis:
CXCR4 mRNA levels are expressed as arbitrary units. In this experi-
ment, the basal CXCR4 mRNA level appears higher compared with
other experiments, as we exposed the film for a longer period for better
visualization of the blot.T
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that HIF-1 activation is involved in the Hyp-dependent
up-regulation of CXCR4 expression and that the Hyp–
HIF-1–CXCR4 circuit may participate in pathophysiolog-
ical mechanisms under several conditions, ranging from in-
flammation to tumor angiogenesis and metastasis.
In contrast to standard cell culture conditions, character-
ized by 20% oxygen concentration, cells in the human
body are exposed to much lower oxygen concentrations,
ranging from 16% in the pulmonary alveoli to  6% in
most other organs of the body. Moreover, oxygen concen-
tration may even drop to extremely low concentrations,
close to anoxia, in the presence of altered vascularization as
observed at pathological sites such as tumors (1). As selec-
tive accumulation of leukocyte subpopulations is the hall-
mark in allergy, inflammation, and tumors (18), it was
important to investigate how leukocyte recruitment is af-
fected by changes in oxygen tension. We first observed
that in response to Hyp monocytes and MDM increase,
CXCR4 expression and function, as assessed by surface ex-
pression and chemotactic responsiveness to its specific
ligand CXCL12. Thus, dynamic regulation of the chemo-
tactic responsiveness of monocytes/macrophages may rep-
resent a feature of the pathophysiology of inflammatory
diseases associated with Hyp. Interestingly, Hyp is present
in the joint microenvironment, because articular cartilage
is an avascular tissue that functions at lower oxygen tension
than do most tissues. Moreover, in the setting of diseases
such as rheumatoid arthritis and osteoarthritis, in which
macrophages promote perpetuation of chronic inflamma-
tion (39), a further decrease in synovial fluid oxygen ten-
sion may occur (40, 41).
In solid tumors, TAMs represent a prominent compo-
nent of the mononuclear leukocyte population, which dis-
plays an ambivalent relationship with tumors (the “macro-
phage balance hypothesis”; reference 17). Interestingly,
TAMs preferentially localize at the tumor–host tissue inter-
face, in regions often associated with low oxygen tensions.
Several lines of evidence also indicate that chemokines play
a pivotal role in the recruitment of monocytes in neoplastic
tissues (17, 18, 42) and a variety of chemokines have been
detected as products of cancer cells or tumor stromal ele-
ments. In particular, CCL2 was proposed as tumor-derived
chemotactic factors, which play a major role in the recruit-
ment of macrophages at the tumor site (18). Receptor ex-
pression is a crucial determinant of the spectrum of action
of chemokines (18). It was reported that the capacity of
monocytes/macrophages to migrate in response to CCL2 is
decreased in low oxygen conditions (4, 5). Thus, our ob-
servation of Hyp-mediated up-regulation of CXCR4 ex-
pression in TAMs may indicate that in regions associated
with oxygen decrease, a dynamic change of their receptor
profile occurs, with up-regulation of functional CXCR4.
In support of this hypothesis, Cramer et al. have recently
shown that myeloid cell infiltration in vivo is dependent on
the presence of an intact HIF-1  subunit, suggesting that
oxygen gradient may be a critical factor for myeloid cells’
migration in inflammatory sites (43). A relay of distinct
chemokine–chemokine receptor interactions may regulate
initial recruitment, tissue infiltration in hypoxic areas, and
in neoplastic and non-neoplastic inflammatory sites in a
multistep navigation process (44).
Angiogenesis is a prerequisite for the expansion of solid
tumors and is often activated during the early, preneoplastic
stages of tumor development (45, 46). Tumor angiogenesis
is controlled by a number of positive and negative regulators
produced by cancer cells and tumor-associated leukocytes.
A number of molecules with possible impact on angiogene-
sis have been shown to be expressed by macrophages in low
oxygen conditions, such as VEGF, TNF- , bFGF, and
CXCL8 (47). The contribution of chemokines toward an-
giogenesis is currently a focus of intensive investigation (48).
Strikingly, it was recently reported that CXCL12 acts as a
potent chemoattractant for endothelial cells of different ori-
gins bearing CXCR4 and is a participant in angiogenesis
that is regulated at the receptor level by VEGF and bFGF
(31, 49–51). In agreement with these observations, we ob-
served an increased chemotactic responsiveness of HUVECs
toward CXCL12, which may well be part of the Hyp-
induced angiogenic program. Hyp is a well-recognized
pathophysiological condition for the induction of angio-
genic factors, including but not limited to VEGF (16). In
agreement with these observations, our data suggest that the
angiogenic program established by Hyp may rely also on the
increased expression of CXCR4 by different cellular com-
ponents in the tumor microenvironment, including endo-
thelial cells, tumor cells, and TAMs.
The involvement of CXCR4 in cancer metastasis has
been proposed by Muller and colleagues, who showed that
this receptor and its ligand (CXCL12) together govern the
pattern of breast cancer metastasis in a mouse model (33,
52). This observation is in support of the “chemoattrac-
tion” theory of metastasis, which holds that organ-specific
attractant molecules stimulate the migrating tumor cells to
invade the walls in blood vessels and enter the organs.
However, this remarkable observation does not clarify the
mechanisms of selection by which cancer cells became
CXCR4 positive. Our observation that the levels of
CXCR4 surface expression induced by Hyp are sustained
for several hours after reoxygenation is consistent with the
idea that this pathway may confer metastatic potential to
cancer cells. Indeed, it was described in in vivo models of
metastasis that after entering the circulation, the majority of
cancer cells home to target organs in a timeframe ranging
from 1 to 24 h (53). We propose that in solid tumors, in
addition to genetic alterations such as mutation of VHL,
PTEN, or p53 genes that are associated with increased lev-
els of HIF-1 transcriptional activity, microenvironmental
Hyp may increase CXCR4 expression and the metastatic
potential of cancer cells. In line with this hypothesis, recent
evidence has been provided that invasive cancer phenotype
is associated with Hyp and/or HIF-1  overexpression (54).
In agreement with the data and concepts described here, by
using immunohistochemical analysis, we have observed
that ductal carcinoma cells from breast tissue located in ar-
eas of intratumoral necrosis display nuclear HIF-1  expres-
sion and high levels of CXCR4 (unpublished data).T
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HIF-1 activates transcription of genes that mediate adap-
tive responses to reduced oxygen availability and a number
of HIF-1–regulated genes have been identified, whose
products play key roles in angiogenesis, vascular reactivity
and remodelling, and glucose and energy metabolism (1).
HIF-1 is a heterodimer composed of a HIF-1  subunit that
is constitutively expressed and a HIF-1  subunit that is rap-
idly degraded by ubiquitination via the proteasomal path-
way, a process that is inhibited under hypoxic conditions.
Oxygen-regulated destruction of HIF-1  requires the von
Hippel–Lindau tumor suppressor protein (pVHL) (34, 35).
pVHL acts as the recognition component of a ubiquitin E3
ligase complex, which binds HIF-1 , and loss of pVHL
function results in constitutive activation of the hypoxic
response (35, 55). A role for HIF-1 in the regulation of
CXCR4 mRNA expression is suggested by the following
findings: (a) mouse embryonal fibroblast lacking the   sub-
unit of HIF-1 had impaired hypoxic induction of CXCR4
mRNA; (b) CXCR4 mRNA was differentially expressed
in the renal cancer cell lines 786.0 and WT2 bearing a
VHL-mutated and WT phenotype, respectively; (c) Hyp
or cotransfection of a HIF-1  expression vector–induced
transcriptional activation of a 2.6-kb CXCR4 promoter lu-
ciferase reporter construct; (d) ChIP analysis demonstrated
that after Hyp, HIF-1  is specifically recruited to the
CXCR4 promoter, in the nucleotide region  1860 to
 1578; and (e) the HIF-1 inhibitor Topotecan inhibited
the Hyp-induced expression of CXCR4 in CAOV3 cells.
A sequence homology search of the region  1860 to
 1578 of the CXCR4 promoter revealed the presence
of a putative HIF-1 binding site at position  1725 (5 -
GCGTG-3 ). Ongoing studies in the laboratory will pro-
vide a full biochemical and functional characterization of
the HRE. In addition to transcriptional activation, we
found that Hyp further contributes to increased CXCR4
gene expression by stabilization of CXCR4 transcripts,
suggesting that Hyp-regulated RNA binding factors may
interact with and stabilize the CXCR4 mRNA at the post-
transcriptional level.
Our data identify the Hyp–HIF-1–CXCR4 pathway as
a relevant molecular circuit in the functional tuning of the
chemokine system. The validity of this observation in dif-
ferent cell types (mononuclear phagocytes, HUVECs, fi-
broblasts, and cancer cells), consistent with the virtually
universal expression of the Hyp–HIF-1 pathway in mam-
malian cells, argues in favor of its potential involvement in
the pathophysiology of diverse conditions. In a multistep
navigation process, the Hyp–HIF-1 –CXCR4 pathway
may regulate trafficking and localization in hypoxic tissues
and represents a target for novel therapeutic strategies.
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